Plaintiffs Par Pharmaceutical Inc and Handa Pharmaceutical (collectively plaintiffs) filed a complaint against Defendants Takeda Pharmaceutical Co Ltd for a Declaratory Judgment of patent non-infrigment and invalidity over the Takeda's drug Dexilant® (dexlansoprazole).
Plaintiffs seek a declaratory judgment of non-infringement and/or invalidity of U.S. patent No. 8,461,187 pursuant to the patent laws of the united states, 35 U.S.C. §§ 1 et seq and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 et seq.
Complaint for Declaratory Judgement:
Civil Action No. 3:13-cv-03151-EDL, the Hon. Elizabeth D. Laporte presiding.
Filed on July 9, 2013 in the U.S. District Court for the Northern District of California
Patent in suit: US 8,461,187
Further, previously Takeda brought a patent infrigment action (Case no: 3:11-cv-00840-jcs) against Handa and Par Pharmaceuticals for U.S. patent Nos. 6,462,058; 6,664,276; 6,939,971; 7,285,668; 7,790,755 is currently pending in the U.S District court for the Distrcit court of Northeren California.
Plaintiffs seek a declaratory judgment of non-infringement and/or invalidity of U.S. patent No. 8,461,187 pursuant to the patent laws of the united states, 35 U.S.C. §§ 1 et seq and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 et seq.
Complaint for Declaratory Judgement:
Civil Action No. 3:13-cv-03151-EDL, the Hon. Elizabeth D. Laporte presiding.
Filed on July 9, 2013 in the U.S. District Court for the Northern District of California
Patent in suit: US 8,461,187
Further, previously Takeda brought a patent infrigment action (Case no: 3:11-cv-00840-jcs) against Handa and Par Pharmaceuticals for U.S. patent Nos. 6,462,058; 6,664,276; 6,939,971; 7,285,668; 7,790,755 is currently pending in the U.S District court for the Distrcit court of Northeren California.